Viking Therapeutics, Inc. (VKTX) Fundamental Analysis: Bull vs. Bear Case

VKTX

Viking Therapeutics, Inc.

Fundamental data last updated:October 24, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

VALUATION

P/E

-7.88

Market Cap ($M USD)

$3.74B

Forward P/E

14.66 PEG

0.10 PRICE TO SALES

0.00 PRICE TO BOOK

7.41 EV / EBITDA

-7.21

5-Year Average P/E

Free Cash Flow Yield

-9.11%

DCF Value

$1.03

Graham Number

N/A

Price to FCF

-10.98

EV to FCF

-10.63

Earnings Yield

-12.70%

FCF Yield

-9.11%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$4.09

Next Year EPS Growth Estimate

$2.20

Next Year Revenue Growth Estimate

$1.21B

Return on Equity (ROE)

-71.31%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.00 Piotroski F-Score

1 Altman Z-Score

17.04 Return on Invested Capital (ROIC)

-100.02%

Current Ratio

5.72 Quick Ratio

5.72 Net Debt to EBITDA

0.24 Interest Coverage

-15687.44

Gross Profit margin

0.00%

FCF PER SHARE

$-2.94

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

Viking Therapeutics, Inc. is priced for perfection, yet the numbers tell a different story. Despite a forward P/E of 14.27 suggesting potential growth, the stock’s valuation is starkly misaligned with its DCF value. The negative earnings yield and a staggering Altman Z-score of 16.48 indicate financial safety, but the market cap dwarfs the intrinsic value, hinting at overvaluation. The company’s negative ROIC and earnings suggest a struggle to generate shareholder value, overshadowing any optimism from the forward earnings estimate.

AI Exposure / Tech Reliance

In the rapidly evolving biotech sector, Viking Therapeutics is positioned to leverage AI advancements in drug discovery and personalized medicine. However, the company's current financial metrics do not reflect a robust adaptation to these technological shifts. The industry demands innovation, and Viking's current execution may not be sufficient to capitalize on these opportunities.

The Bull Case

For the optimistic investor, Viking Therapeutics offers a tantalizing growth narrative. The forward PEG ratio of 0.09 is a beacon for GARP investors, indicating potential undervaluation relative to growth. Despite a dismal Piotroski F-Score of 1, the company's negligible debt and high current ratio suggest financial resilience. The market's consensus rating of "Buy" reflects institutional confidence in its future prospects, driven by anticipated sales growth.

The Bear Case

Yet, the bear case is hard to ignore. Viking's Price/Book ratio of 7.21 and negative EV to EBITDA highlight a valuation stretched thin. The company's inability to generate positive free cash flow, as evidenced by a negative FCF yield, raises red flags about its operational efficiency. Trading close to its 52-week high, the stock appears technically overextended, with no tangible earnings to justify its lofty market cap.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$93.60

Institutional Ownership %

1-Year Beta

0.71 Insider Buying % (6 Mo)

Distance to 52-Week High

34.05%

Distance to 52-Week Low

28.68%

EARNINGS SURPRISE %

-35.64%

50-DAY SMA

$32.53

200-DAY SMA

$32.52

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.